Published : 01 Dec 2015

---

Aagami successfully facilitated Investments and partnering for an oncology focused Louisiana Biotech Company. This has enabled them to further develop their technologies and pipeline of targeted therapies and therapeutic vaccines.

Client is a clinical-stage bio-pharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. They have a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. They are headquartered in Baton Rouge, LA, US.

Solution Approach

• Aagami scanned the global market, identified right investors/ partners, and took them to 50 + companies.
• With focused efforts 10+ companies had post CDA level scientific and clinical discussions.
• Aagami kept facilitating and persevering, 3 companies moved to term sheet level discussions.
• Finally Aagami found a right partner to facilitate reverse merger with a OTC Markets listed company.
• This is enabling access to large sums of funds to develop clinical stage programs.

 

Results

• Listing on OTC Markets by a reverse merger
• Financial resources to enable development of existing pipeline and technologies.